Augmentation Strategies for Inadequate Antidepressant Response: A Review of Placebo-Controlled Studies

References

• Coryell W, Endicott J, Winokur G, et al: Characteristics and significance of untreated major depressive disorder. Am J Psychiatry 1995; 152:1124–1129
   PubMed Web of Science ®Google Scholar
• RiekeIs K, Schweizer E, Clary C. Fox I, Weise C: Nefazodone and imipramine in major depression: A placebo-controlled trial. Br J Psychiatry 1994; 164:802–805
   Google Scholar
• Brown, WA: Predictors of placebo response in depression. Psychopharmacol Bull 1988; 24:14–17
   PubMed Web of Science ®Google Scholar
• Brown WA, Johnson MF, Chen MG: Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992; 41:203–214
   PubMed Web of Science ®Google Scholar
• Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M: Which Depressions Respond to Placebo? Psychiatry Res 1986; 18:217–226
   PubMed Web of Science ®Google Scholar
• Kahn A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL: Chronicity of depressive episode in relation to antidepressant/placebo response. Neuropsychopharmacology 1991; 4:125–130
   Google Scholar
• Schweizer E, RiekeIs K, Amsterdam JD, Fox I, Puzzuoli G, Weise C: What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990; 51:8–11
   PubMed Web of Science ®Google Scholar
• Stewart JW, Ouitkin FM, McGrath PJ, et al: Use of pattern analysis to predict differential relapse of remitted patients with major depression during one year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55:334–343
   PubMed Web of Science ®Google Scholar
• Heninger GR, Charney DS, Sternberg DE: Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychia-try 1983; 40:1335–1342
   PubMed Web of Science ®Google Scholar
• Schopf J, Baumann P, Lemarchand T, Ray M: Treatment of endogenous depressions resistant to antidepressants or related drugs by a lithium addiction. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989; 22:183–187
   Google Scholar
• Stein G, Burnadt M: Lithium augmentation therapy in tricyclic-resistant depression. Br J Psychiatry 1993; 162: 634–640
   PubMed Web of Science ®Google Scholar
• Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine aug-mentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387–393
   PubMed Web of Science ®Google Scholar
• Katona CLE, Abou-Salah MT, Harrison DA, et al: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80–86
   PubMed Web of Science ®Google Scholar
• Baumann P. Souche A, Montaldi S, et al: A double-blind, placebo-controlled study of citalopram with and without lith-ium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investiga-tion. J Clin Psychopharmacol 1996; 6:307–314
   Google Scholar
• Zusky P, Biederman J, Rosenbaum J, et al: Adjunct low dose lithium carbonate in treatment resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988; 8:120–124
   PubMed Web of Science ®Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neuro-surg Psychiatry 1960; 23:56–62
   PubMed Web of Science ®Google Scholar
• Grube F, Hartwich P: Maintenance of antidepressant effect of sleep deprivation with the help of lithium. Eur Arch Psychiatry Clin Neurosci 1990; 240:60–61
   Google Scholar
• Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E: Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol 1999; 19:240–245
   PubMed Web of Science ®Google Scholar
• Gitlin M, Weiner H, Fairbanks L, Hershman J, Friedfeld N: Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord 1987; 13:267–272
   PubMed Web of Science ®Google Scholar
• Thase ME, Kupfer JD, Jarrett DB: Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50: 383–388
   Google Scholar
• Joffe RT, Singer W: A comparison of triiodothyronine and thyroxin in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32:241–251
   PubMed Web of Science ®Google Scholar
• Bunevicius R, Cazanavicius G, Zalinkevicius R, Prange AJ: Effects of thyroxine as compared with thyroxine plus triiodo-thyronine in patients with hypothyroidism. N Eng J Med 1999; 340:424–429
   PubMed Web of Science ®Google Scholar
• Macs M, Vandoolaghe E, Desnyder R: Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41:201–210
   Google Scholar
• Perez V, Soler J, Puigdemont D, Alvarez E, Afectius G, Arti-gas F: A double-blind randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999; 56:375–379
   PubMed Web of Science ®Google Scholar
• Perez V. Gilaberte I, Faries D, Alvarez E, Artigas F: Random-ized, double-blind, placebo-controlled trial of pindolol in com-bination with fluoxetine antidepressant treatment. Lancet. 1997; 349:1594–1597
   PubMed Web of Science ®Google Scholar
• Tome MB, Isaac MT, Harte R, Holland C: Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12:81–89
   PubMed Web of Science ®Google Scholar
• Zanardi R, Artigas F, Franchini L, et al: How long should pindolol be associated with paroxetine to improve the anti-depressant response? J Clin Psychopharmacology 1997; 17:146–150
   Google Scholar
• Bordet R, Thomas P, Dupuis B: Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998; 155:1346–1351
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J: Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998; 18:441–446
   PubMed Web of Science ®Google Scholar
• Berman RM, Anand A, Cappiello A, et al: The use of pindololwith fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psy-chiatry 1999; 45:1170–1177
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. Neuropsychopharmacol-ogy 1999; 20:380–385
   PubMed Web of Science ®Google Scholar
• Zweifel JE and O'Brien WH: A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22:189–212
   PubMed Web of Science ®Google Scholar
• Klaiber EL, Broverman DM, Vogel W, Kobayashi T: Estro-gen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979; 36:550–554
   PubMed Web of Science ®Google Scholar
• Shapira B, Oppenheim G, Zohar J, Segal M, Malach D, Bel-maker RM: Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 1985; 20:576–579
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus DIAGNOSIS, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E: Double-blind treat-ment of major depression with the dehydroepiandrosterone. Am J Psychiatry 1999; 156:646–649
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR: Dehydroepiandrosterone treatment of mid-life dysthy-mia. Biol Psychiatry 1999; 45:1533–1541
   PubMed Web of Science ®Google Scholar